$TWST

WERNER ROBERT F. sold $94K of TWST

WERNER ROBERT F. (Chief Accounting Officer) sold 1,359 shares of Twist Bioscience Corp (TWST) at an average of $69.20 ($69.07–$69.84) across 2 trades on 2026-06-08.

Original reporting
SEC EDGAR · WERNER ROBERT F.
Published Jun 10, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
high confidence
Mentioned
$TWST
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The newest information is the specific insider sale details (shares, prices, and post-transaction holdings).

02

Market read

Traders may monitor for clustering of insider sales or subsequent filings, but this single sale is not a standalone fundamental catalyst.

03

What to watch

The absence of a 10b5-1 plan could increase speculation, but without follow-on filings or company disclosures it remains weak evidence for direction.

Relevance 3/10Novelty 8/10Timing: Filed 2026-06-10 for a sale executed 2026-06-08

Background

The article is an SEC Form 4 insider transaction report for Twist Bioscience.

Company-level read

Ticker impact

$TWSTNeutralHigh confidence
Context

Twist Bioscience disclosed an open-market sale by its Chief Accounting Officer: 1,359 shares sold at ~$69.20 (Form 4).

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction (open-market sale) with no 10b5-1 plan and no accompanying corporate event, guidance, or operational update.

Market effects

No clear sector read-through; insider sales are generally idiosyncratic absent additional company news.

None indicated.

None indicated.

Counterpoint

Because the sale is small relative to typical liquidity and lacks any stated reason, it may reflect diversification/tax planning rather than bearish expectations.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider transaction disclosure.

  • Robert F. Werner

    Chief Accounting Officer who sold 1,359 shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.